PA8779601A1 - Azetidinas - Google Patents

Azetidinas

Info

Publication number
PA8779601A1
PA8779601A1 PA20088779601A PA8779601A PA8779601A1 PA 8779601 A1 PA8779601 A1 PA 8779601A1 PA 20088779601 A PA20088779601 A PA 20088779601A PA 8779601 A PA8779601 A PA 8779601A PA 8779601 A1 PA8779601 A1 PA 8779601A1
Authority
PA
Panama
Prior art keywords
antagonist
azetidins
leiomiomas
azetidines
endometriosis
Prior art date
Application number
PA20088779601A
Other languages
English (en)
Inventor
Neil Dack Kevin
Elizabeth Skerratt Sarah
Kuen Yeap Siew
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PA8779601A1 publication Critical patent/PA8779601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA CLASE DE AZETIDINAS ANTAGONISTAS DE EP2 DE FÓRMULA GENERAL ( I ) EN LA QUE LAS VARIABLES Y SUSTITUYENTES SON COMO SE DEFINEN EN ESTE DOCUMENTO, Y ESPECIALMENTE A COMPUESTOS ANTAGONISTAS DE EP2, A SU USO EN MEDICINA, PARTICULARMENTE EN EL TRATAMIENTO DE ENDOMETRIOSIS Y/O MIOMAS UTERINOS ( LEIOMIOMAS ) Y A PRODUCTOS INTERMEDIOS ÚTILES EN SU SÍNTESIS Y A COMPOSICIONES QUE LOS CONTIENEN.
PA20088779601A 2007-05-10 2008-05-08 Azetidinas PA8779601A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91708107P 2007-05-10 2007-05-10
US1303007P 2007-12-12 2007-12-12

Publications (1)

Publication Number Publication Date
PA8779601A1 true PA8779601A1 (es) 2009-01-23

Family

ID=39739736

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088779601A PA8779601A1 (es) 2007-05-10 2008-05-08 Azetidinas

Country Status (27)

Country Link
US (1) US20080280877A1 (es)
EP (1) EP2155666A1 (es)
JP (1) JP2010526801A (es)
KR (1) KR20100009582A (es)
CN (1) CN101679235A (es)
AP (1) AP2009005047A0 (es)
AR (1) AR066524A1 (es)
AU (1) AU2008249744A1 (es)
BR (1) BRPI0811444A2 (es)
CA (1) CA2686517A1 (es)
CL (1) CL2008001305A1 (es)
CO (1) CO6260066A2 (es)
CR (1) CR11101A (es)
DO (1) DOP2009000256A (es)
EA (1) EA200901381A1 (es)
EC (1) ECSP099727A (es)
GT (1) GT200900293A (es)
IL (1) IL201874A0 (es)
MA (1) MA31366B1 (es)
MX (1) MX2009011998A (es)
PA (1) PA8779601A1 (es)
PE (1) PE20090282A1 (es)
SV (1) SV2009003407A (es)
TN (1) TN2009000470A1 (es)
TW (1) TW200904409A (es)
UY (1) UY31070A1 (es)
WO (1) WO2008139287A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222665A1 (en) * 2007-11-15 2010-09-01 Pfizer Limited Azetidines as ep2 antagonists
KR20110083733A (ko) * 2008-11-10 2011-07-20 화이자 리미티드 피롤리딘
JP2012522796A (ja) * 2009-04-02 2012-09-27 アラーガン インコーポレイテッド プロスタグランジンｅレセプター拮抗薬
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
TWI589576B (zh) 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
WO2016103097A1 (en) 2014-12-22 2016-06-30 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
WO2022272062A1 (en) * 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8300860D0 (en) * 1983-01-13 1983-02-16 Shell Int Research Azetidine compounds
GB8415614D0 (en) * 1984-06-19 1984-07-25 Shell Int Research Azetidine derivatives
GB8509746D0 (en) * 1985-04-16 1985-05-22 Shell Int Research Preparing azetidine derivatives
AR037364A1 (es) 2001-11-16 2004-11-03 Schering Corp Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
CN109053523B (zh) * 2005-10-07 2022-03-25 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives

Also Published As

Publication number Publication date
CA2686517A1 (en) 2008-11-20
JP2010526801A (ja) 2010-08-05
US20080280877A1 (en) 2008-11-13
DOP2009000256A (es) 2009-11-30
CO6260066A2 (es) 2011-03-22
ECSP099727A (es) 2009-12-28
SV2009003407A (es) 2010-01-12
AR066524A1 (es) 2009-08-26
TW200904409A (en) 2009-02-01
KR20100009582A (ko) 2010-01-27
AP2009005047A0 (en) 2009-12-31
EA200901381A1 (ru) 2010-06-30
CL2008001305A1 (es) 2008-07-18
TN2009000470A1 (fr) 2011-03-31
PE20090282A1 (es) 2009-03-27
EP2155666A1 (en) 2010-02-24
UY31070A1 (es) 2009-01-05
MX2009011998A (es) 2009-11-19
MA31366B1 (fr) 2010-05-03
CR11101A (es) 2009-12-04
AU2008249744A1 (en) 2008-11-20
WO2008139287A1 (en) 2008-11-20
BRPI0811444A2 (pt) 2014-10-29
CN101679235A (zh) 2010-03-24
IL201874A0 (en) 2010-06-16
GT200900293A (es) 2010-05-17

Similar Documents

Publication Publication Date Title
PA8779601A1 (es) Azetidinas
CR10219A (es) Piperidinoil pirrolidinas agonistas del receptor de melanocrotina tipo 4.
CY1117878T1 (el) Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2
CY1117441T1 (el) Αρυλοαιθινυλο παραγωγα
CY1116333T1 (el) Παραγωγα βενζοφουρανιου ως ρυθμιστικα μορια των fxr
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
HN2012001162A (es) Triazolopiridinas
ECSP11011439A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CR20120264A (es) Compuestos
SV2011003853A (es) Compuestos organicos
CY1115994T1 (el) Φαρμακευτικες τυποποιησεις οι οποιες περιεχουν προσδεματα υποδοχεα ντοπαμινης
PA8815201A1 (es) Compuestos heterociclicos
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
GT201300254A (es) Triazolopiridinas
EA201101699A1 (ru) Синергетические фунгицидные смеси
CY1115673T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν 2-οξο-1-πυρρολιδινο παραγωγα
HN2011000076A (es) Derivados de piridino-piridinonas, su preparacion.
ECSP088527A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
PA8855001A1 (es) Monocarbamas
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
CO6341625A2 (es) Derivados de indol como agentes anticáncer